Current and future options in cholesterol lowering treatments
Author:
- 20 February 2023
- journal article
- review article
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 112, 1-5
Abstract
No abstract availableKeywords
This publication has 65 references indexed in Scilit:
- ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPKJournal of Lipid Research, 2013
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsThe Lancet, 2010
- Therapeutic Options to Further Lower C-Reactive Protein for Patients on Statin TreatmentCurrent Atherosclerosis Reports, 2010
- Drug-Induced Liver Injury Associated with StatinsSeminars in Liver Disease, 2009
- Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and CancerJACC, 2007
- EzetimibeClinical Pharmacokinetics, 2005
- Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trialClinical Therapeutics, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Perspectives in Cholesterol-Lowering TherapyCirculation, 2003